JPRN-UMIN000027795尚未招募未知
The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer. - The efficacy of Abirateron and Dutasteride for CRPC.
Department od Urology, Yamaguchi Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2017年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 90years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1)Patients took 5alpha-reductase inhibitors previously 2)AST >101 IU/L or ALT>101 IU/L or Child-Pugh score C 3)HbA1c > 10% 4)serum potassium < 3.5 mEq/l
研究者
相似试验
进行中（未招募）
1 期
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentEUCTR2012-004331-23-GBJanssen-Cilag International NV164
进行中（未招募）
1 期
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004331-23-HUJanssen-Cilag International NV144
进行中（未招募）
1 期
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004331-23-BEJanssen-Cilag International NV144
进行中（未招募）
1 期
A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsEUCTR2012-004331-23-ITJanssen-Cilag International NV164
进行中（未招募）
1 期
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004331-23-DEJanssen-Cilag International NV164